News

Milestone Scientific Welcomes Dr. Sayed to Board for Progress

Milestone Scientific Welcomes Dr. Sayed to Board for Progress

Milestone Scientific's Strategic Addition of Dr. Dawood Sayed

Milestone Scientific Inc. (MLSS), a pioneer in the development of advanced drug delivery systems, has announced the appointment of Dr. Dawood Sayed to its Board of Directors. Dr. Sayed, a recognized authority in interventional pain medicine, will provide invaluable insights as the company pursues its goals in innovative pain management.

About Dr. Dawood Sayed's Expertise

Dr. Sayed is currently a Professor of Anesthesiology and Pain Medicine at the University of Kansas Medical Center. His roles include Division Chief of Pain Medicine and Director of Interventional Spine Services. His extensive experience and deep understanding of minimally invasive procedures equip him to enhance Milestone Scientific's mission.

Contributions to Pain Management

In addition to his academic roles, Dr. Sayed is the Vice Chairman and Co-Founder of the American Society of Pain and Neuroscience (ASPN). His influence extends through collaborations with commercial payers and regulators to ensure access to advanced pain relief technologies. His leadership has been recognized with various awards, including the prestigious Presidential Award from the North American Neuromodulation Society.

Company Insights on Strategic Growth

Neal Goldman, Chairman of Milestone Scientific, expressed enthusiasm about Dr. Sayed’s appointment. He believes that Dr. Sayed’s profound expertise will be crucial for the company's expansion in the pain management sector. This strategic decision fills a vital role in ensuring that Milestone Scientific adapts to both patient and physician needs in a dynamic healthcare environment.

The Impact of CompuFlo® Technology

Milestone Scientific’s CompuFlo® Epidural System represents a transformative technology that enhances safety and precision during injections. This real-time feedback mechanism allows practitioners to accurately identify the epidural space, improving overall procedural outcomes and reducing the risks often associated with traditional methods.

A Future Driven by Innovation

Looking toward growth, Eric Hines, CEO of Milestone Scientific, emphasized that Dr. Sayed’s background will aid in developing strategies for clinical adoption and reimbursement. As the company embraces this next stage, it aims to solidify its presence in the interventional pain management field. Dr. Sayed is eager to play a part in this journey, advocating for innovative solutions that improve patient safety and reduce reliance on opioids.

Advancements in Clinical Research

With over 100 peer-reviewed publications and contributions to national pain management guidelines, Dr. Sayed is actively involved in multiple clinical trials dedicated to neuromodulation and spinal therapies. His role as a medical advisor to leading technology innovators enhances his ability to guide Milestone Scientific in navigating the evolving landscape of medical technology.

About Milestone Scientific Inc.

Milestone Scientific Inc. is committed to revolutionizing the medical and dental fields with its patented technologies designed for improved injection techniques. Utilizing its unique Dynamic Pressure Sensing Technology (DPS®), Milestone’s systems aim to increase efficiency and comfort, while also ensuring patient safety.

Frequently Asked Questions

What is Milestone Scientific Inc. known for?

Milestone Scientific is known for developing innovative drug delivery technologies, particularly aimed at improving pain management outcomes.

Who is Dr. Dawood Sayed?

Dr. Dawood Sayed is a leading expert in interventional pain medicine, appointed to Milestone Scientific’s Board of Directors to enhance its strategic capabilities.

What technology does Milestone Scientific offer?

The company offers the CompuFlo® Epidural System, a technology that uses real-time pressure feedback to improve the accuracy and safety of epidural injections.

What are the goals of Milestone Scientific's recent appointment?

The appointment of Dr. Sayed is aimed at advancing clinical adoption of innovative technologies that improve patient outcomes in pain management.

How does Milestone Scientific approach innovation?

Milestone Scientific invests in research and development to create cutting-edge injection technologies that prioritize patient safety and comfort.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 5

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

SAP Launches Sovereign Cloud Solution in Canada for Businesses

Updated Category News Views 365

SAP Enhances Data Security with New Cloud Solutions SAP SE shares are experiencing a positive trend in premarket trading. Recently, SAP Canada introduced its innovative SAP Sovereign Cloud capabilities, which are designed to address the increasing demand from organizations for data sovereignty, robust security, and regulatory compliance. This pioneering solution enables...

Continue Reading
Corbus Pharma's Stock Drops 60%: Analysts Recommend Buying Now

Updated Category News Views 92

Corbus Pharmaceuticals Sees Significant Stock Drop Amid Market Responses Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has recently faced a dramatic decline in its stock, plummeting by an alarming 60%. However, analysts are encouraging investors to view this as a potential buying opportunity. Firms like H.C. Wainwright and Oppenheimer have reaffirmed their buy...

Continue Reading
Manatt Welcomes New Partner with Extensive Investment Expertise

Updated Category News Views 139

Manatt's Strategic Growth in Corporate Practice Manatt, Phelps & Phillips, LLP is making waves in the corporate legal landscape with its recent addition of Peter Tsirigotis, a seasoned investment funds partner. This move reflects the firm's commitment to expanding its financial services and corporate capabilities. Based in Washington, D.C., Tsirigotis brings a wealth of...

Continue Reading
Performance Share Units Vesting: ISS A/S Updates Details

Updated Category News Views 216

Performance Share Units Vesting Announcement ISS A/S is proud to announce the significant milestone concerning its long-term incentive program (LTIP). As part of this initiative, a number of Performance Share Units (PSUs) have recently vested, leading to the delivery of ISS shares to key personnel within the company. This process, which emphasizes the company's commitment...

Continue Reading
Omnicom Boosts Dividend: New Shareholder Benefit Unveiled

Updated Category News Views 196

Omnicom Boosts Dividend for Shareholders Omnicom, a renowned leader in marketing and sales, has officially announced an increase in its quarterly dividend to $0.80 per share. This enhancement reflects a significant increase in the company's commitment to its shareholders, offering both immediate rewards and a long-term strategy for growth. Dividend Increase Overview The...

Continue Reading